Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab
| Autor: | Nicolas Magné, Catherine Genestie, Jean-Christophe Vaillant, David Khayat, Frédérique Capron, A. Bellanger, Julien Domont, A. Barbier, Jean-Philippe Spano, J.-L. Goldmard, C. Hannoun |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Adult Cyclin-Dependent Kinase Inhibitor p21 Male Vascular Endothelial Growth Factor A Cancer Research medicine.medical_specialty Lung Neoplasms Bevacizumab Colorectal cancer Cetuximab Antineoplastic Agents Antibodies Monoclonal Humanized Irinotecan Metastasis Internal medicine medicine Biomarkers Tumor PTEN Humans Radiology Nuclear Medicine and imaging Aged biology business.industry Liver Neoplasms PTEN Phosphohydrolase Antibodies Monoclonal Hematology General Medicine Middle Aged medicine.disease Primary tumor Neoplasm Proteins ErbB Receptors biology.protein Biomarker (medicine) Immunohistochemistry Camptothecin Female business Colorectal Neoplasms Proto-Oncogene Proteins c-akt medicine.drug |
| Zdroj: | Bulletin du cancer. 97(2) |
| ISSN: | 1769-6917 |
| Popis: | Background Recent studies suggested substantial differences between primary tumors and metastases for EGFR expression in colorectal cancer (CRC). The aim of the study was to correlate the expression of a panel of molecular markers between primary CRC samples and metastases. Methods Expressions of EGFR, pEGFR, VEGF, pVEGF, PTEN, pAKT and p21 were analyzed in 28 primary tumors and 32 liver metastases by immunohistochemistry performed on formalin-fixed, paraffin-embedded sections from 46 CRC patients. The molecular profiles were evaluated by tissue micro-array. The correlation between tumor and metastasis biomarker expressions was tested. Results Among 60 CRC samples, 25% were EGFR positive, 38% were pEGFR positive, 38%were VEGF positive, 48% were pVEGF positive, 70% were pAKT positive and 51%were p21 positive. PTEN was deleted in 39% of cases and absence of p21 expression was found in 49% of cases. Asignificant correlation was observed between primary tumors and metastases for pAKT (p = 0.037) and pEGFR (p = 0.0002) status. In patients treated with cetuximab-based therapy (n = 18), p21 appeared as a significant predictive factor of response (p = 0.036). Conclusion Biomarkers status may change between primary and metastatic sites in CRC, with potential implications for the identification of patients who are likely to respond to anti-EGFR treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|